common-close-0
BYDFi
Trade wherever you are!
1H1D1W1M

Generalize

Information

Data from

CDBIO is a medical foundation based in the Republic of Seychelles that provides molecular medical/healthcare services based on advanced molecular physics. The CEO of Idea International, Yasama Yasuhiko, is currently working at the Tohoku Univ Research and Analytical Center for Giant Molecular Studies and is also the CTO of the CDBIO Foundation. Molecular sensors utilizing lithium-resistant fullerene are highly precise technologies that enable disease diagnosis and monitoring of health conditions based on medication effects. This advanced medical technology allows for customized prescriptions and optimized treatments tailored to patient characteristics. CDBIO is developing the Molecular Medical & Healthcare Platform, aiming to create a unique blockchain healthcare ecosystem that combines the expertise of global molecular physics and electrochemical scholars with the collective intelligence of professional medical communities and patient communities. With this platform, CDBIO aims to contribute to human health by enabling early diagnosis of all diseases, providing personalized medical services to individual patients, and promoting disease prevention and systematic healthcare.

Issue Time
1970/01/01
Initial Price
US $ 0.76172121
Circulation/Max
0/1,000.00M
Dominance
0.00%
ROI --%
$0.76172121$4.15384091
Low · 2023/09/112023/09/11 · High

Information

What is CDBIO and its role in molecular-medical/healthcare services?

CDBIO is a medical foundation based in the Republic of Seychelles that specializes in providing advanced molecular physics-based healthcare services. 

Yasama Yasuhiko (Yasama), the CEO of Idea International and a research co-worker at the Tohoku Univ Research and Analytical Center for Giant Molecular Studies, is currently serving as the CTO of the CDBIO Foundation. 

Their molecular sensors, which utilize lithium-resistant fullerene, are highly precise technologies capable of diagnosing diseases and monitoring health conditions based on medication effects. This cutting-edge medical technology enables customized prescriptions and treatments optimized for individual patient characteristics. 

Building upon this technology, CDBIO is developing the Molecular Medical & Healthcare Platform. This platform aims to create a unique blockchain healthcare ecosystem by combining the expertise of global molecular physics and electrochemical scholars with the collective intelligence of professional medical communities and patient communities. 

Through this molecular-medical/healthcare platform, CDBIO aims to contribute to human health by facilitating early disease diagnosis, providing personalized medical services, and promoting disease prevention and systematic health care. 

Answers